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Objectives: Metastatic melanoma is a rare, but aggressive disease that accounts 
for 90% of deaths related to skin cancer. The objective of this project was to 
estimate average direct medical costs associated with treatment of metastatic 
melanoma in a population of Swiss, adult patients from a third-party payer per-
spective. MethOds: Direct medical costs of drugs and services were estimated 
for the following components: Pharmacotherapy; physician visits; inpatient stays; 
outpatient visits; laboratory tests; imaging and other procedures. Unit costs were 
based on 2015 list prices in Swiss Francs (CHF) and derived from the Swiss offi-
cial tariff schedule (TARMED) for outpatient-related costs, Swiss diagnosis-related 
group (DRG) tariffs for inpatient-related costs, the Swiss Federal Office of Public 
Health for laboratory tests and the Swiss drug Compendium for prescription drugs. 
Estimated average cost per patient was population-weighted and reported for 
three mutually-exclusive designed health states: Pre-progression, progression 
and post-progression. Estimates of the utilization of services and the units of 
service received were based on published literature and a survey of Swiss physi-
cians treating melanoma. Results: For pharmacotherapy, the estimated cost 
for a full treatment course was 79’986.09 CHF for ipilimumab, 104’311.59 CHF for 
vemurafenib, and 1’329.89 CHF for dacarbazine. For parenteral drugs the cost of 
administration for a full treatment course was 1’408.73 CHF for ipilimumab and 
2’077.22 CHF for dacarbazine. Average monthly cost for neurosurgery was 1’101.03 
CHF during progression. Outpatient visits accumulated an average per month 
of 27.40 CHF during pre-progression, 92.40 CHF during progression and 170.23 
CHF during post-progression. Other melanoma-related costs (laboratory tests and 
scans) comprised on average 140.70 CHF per month during pre-progression and 
1’182.37 CHF per month during progression. cOnclusiOns: Based on list prices, 
direct medical costs associated with metastatic melanoma treatment were esti-
mated and reported for patients in an adult, Swiss population.
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Objectives: VTE (venous thromboembolism) are among the frequently associated 
with malignant disease events which requires hospitalization and could generate 
extra costs for the health insurance. There is no French studies analyzing the addi-
tional costs induced by VTE and cancer. The objective of this study is to provide an 
estimation of the additional cost induced by VTE + cancer from the analysis of hos-
pital stays extracted from PMSI 2013 (French Hospital Database) for 4 types of cancer 
(breast, lung, hepatocellular carcinoma and colon). MethOds: A crossed approach 
of Principal Diagnosis (DP) and Comorbidities (DAS) was performed to identify all 
stays combining VTE and cancer. The analysis is divided into 3 parts: a descriptive 
approach of hospital stays for VTE + cancer, an analysis by severity level of DRG and 
an economic valorization based on the National Cost Scale. It was not achieved PMSI 
extraction to create a comparison population for each type of cancer because the 
creation of such a population could be a mood point, in particular because of other 
comorbidities may also generated additional costs (eg infection). Public ATIH database 
was used. The essential approach of this study is based on analysis of the distribution 
of stays according to levels of severity DRG. Results: 14,251 stays were analyzed 
combining VTE and cancer. Stays for VTE + cancer represented 81.7% in the severity 
levels 3 and 4. For example, the average cost of lung cancer in cancer patients+ VTE 
(PMSI extraction) is € 7,296 against € 4,647 for this cancer in ATIH database. A multiply-
ing factor is estimated: 1.57 in lung cancer, 1.5 for breast cancer, 1.34 in colon cancer 
and 2.01 for hepatocellular carcinoma. cOnclusiOns: The economic justification 
for the use of preventive treatment of VTE is here in line with clinical guidelines.
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Objectives: Hepatocellular carcinoma (HCC) is the fifth most common malig-
nancy worldwide imposing high hospitalizations and mortality rates and a 
relevant economic burden. Objective of the present analysis is to investigate treat-
ment pathways and healthcare costs for intermediate and advanced HCC patients 
(Barcelona Clinic Liver Cancer Classification (BCLC) stage B and C). MethOds: 
Structured interviews with gastroenterologists and interventional radiolo-
gists were performed in four Italian centres experienced in HCC management. 
Information on disease stage, diagnostic procedures, treatments and healthcare 
resource consumption related to HCC were recorded. Direct healthcare costs 
associated with relevant treatments (sorafenib, Transarterial chemoembolization 
(TACE), transarterial radioembolization (TARE) systemic treatment) were evalu-
ated. Results: Between 2013 and 2014, 285 patients with HCC (mean age 66 years, 
74% males) were treated in the 4 participating centres; of them, 80 were classified 
in the intermediate stage and 57 in the advanced stage. TACE was the most fre-
quent first-line treatment in intermediate stage HCC (63%), followed by sorafenib 
(15%), radiofrequency ablation (14%) and TARE (1,3%). In the advanced stage of HCC 
the most frequently used first-line therapy was sorafenib (56%), followed by best 
therapy. MethOds: Medical records of 220 patients with metastatic SCCHN who 
received ≥ 3 lines of systemic therapy were abstracted. Clinical and demographic 
information at metastatic diagnosis as well as treatment and supportive care data 
were collected for patients ≥ 18 years initiating third-line systemic therapy between 
1 January 2011 and 30 August 2014. Performance status (PS) was recorded prior to 
each line of therapy. SCCHN-related HCRU was captured until death or last medical 
record. All analyses were descriptive. Results: Most patients were Caucasian (90%), 
male (74%), current or former smokers (85%), with an initial SCCHN diagnosis of 
stage IVC (52%). Median age at metastatic diagnosis was 60 years and most patients 
had an Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1 (208/217= 96%). 
For patients with PS= 0/1, the most common first-line treatment was cisplatin+5-
FU (98/208= 47%); docetaxel was the most common second-line (85/177= 48%) and 
third-line treatment (30/117= 26%). For patients with PS≥ 2, the most common first-, 
second-, and third-line treatments were carboplatin+5FU (5/9= 56%), cetuximab 
(12/38= 32%), and methotrexate (21/95= 22%), respectively. Four patients (2%) received 
4 therapy lines while no patient received ≥ 5 lines. Seven patients (3%) received 
radiation and/or surgery for metastatic disease. Most patients received supportive 
care during therapy (85%) and after its discontinuation (89%). SCCHN-related hos-
pitalizations and emergency department visits were reported for 27% and 20% of 
patients during therapy, respectively (vs. 10% and 16% after therapy discontinua-
tion). Median survival after metastatic diagnosis was 25.6 months. cOnclusiOns: 
Patterns of care and HCRU varied among patients with repeatedly treated metastatic 
SCCHN; specific systemic therapies varied by PS. Factors associated with HCRU will 
be examined in future multivariate analyses.
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Objectives: This study aims to evaluate the clinical, medication and economic 
outcome among advanced CRC patients who were relapsed to metastasis in Taiwan 
using reimbursement and cancer registry databases. MethOds: The outcome data 
was form 2 million sampling reimbursement data base of Taiwan’s National Health 
Insurance Research Database (NHIRD) and diseased stage was derived from the 
Taiwan Cancer Registry (TCR) between 2007 and 2011. Diseased stage diagnosed 
for the first time ever of CRC patients was recorded in TCR. Merged database was 
provided by Health and Welfare Statistics Application Center (HWSAC), Ministry of 
Health and Welfare, Taiwan. Metastasis relapse of the advanced CRC patients was 
identified if the patients were prescribed the approved target therapies, i.e. Avastin 
or Erbitux. Descriptive statistics were derived and summarized; Cox regression was 
used to estimate the difference of the relapse proportion and mortality. Results: 
After eliminating the other previous cancer coded in the database, and non- 
reported diseased stages in the merged database. 2,477 patients were derived and 
enrolled into the analysis. Relapse rates were 5.8% and 19.2% among stage III and 
IV CRC patients with median relapse days of 590 and 437. Mortality rates were 21.9 
% and 64.6% with median survival days of 765 and 652. Comparison of the relapse 
rates among different stages was statistical significant with p < 0.0001. Overall costs 
were estimated as an average of 103,616 and 162,714 USD per person during the first 
year since diagnose. cOnclusiOns: Relapse to metastasis stage and mortality rate 
in advanced CRC are still high and estimated medical expenditure increased 57% 
between stage 3 and stage 4 and is possibly due to the high metastatsis relapse rate.
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Objectives: To map the current treatment pathway and resource use in advanced/
metastatic ALK+ non-small cell lung cancer (NSCLC) in Greece, and estimate the 
impact of adding ceritinib in the future treatment pathway. MethOds: An expert 
panel of 7 leading oncologists was convened in order to map the local treatment 
pathway and resource use for ALK+ NSCLC. Published sources provided unit costs 
from the perspective of the Social Insurance Fund (SIF). Direct medical costs were 
included in the analysis: pharmaceutical, medical and hospital care, lab and imaging 
tests, accompanying treatment, and management of AEs and brain metastases for all 
four lines of treatment. Cost base year was 2014. The analysis estimated treatment 
duration based on progression free survival (PFS) from published literature and con-
trolled for estimated brain metastasis frequency by treatment. Results: The current 
treatment pathway in Greece for the management of ALK+ NSCLC utilizes 1st line 
chemotherapy followed by crizotinib, chemotherapy, and palliative care in 2nd, 3rd 
and 4th lines of treatment, respectively. The most widely used 1st line chemothera-
peutic regimen is carboplatin or cisplatin plus pemetrexed (73% of patients); the most 
commonly used 3rd line chemotherapeutic agent is docetaxel (83% of patients). The 
average per patient cost in the current treatment pathway was estimated at € 67,672, 
based on a 20-month treatment duration adjusted for median PFS. The costs associ-
ated with future scenario 1 (crizotinib, ceritinib, chemotherapy, palliative care -treat-
ment duration adjusted to 26 months) and future scenario 2 (chemotherapy, ceritinib, 
chemotherapy, palliative care –treatment duration adjusted to 29.3 months) were 
€ 93,113 and € 105,609, respectively. All cost estimates assumed completion of all four 
lines of treatment and all treatment cycles in each line. cOnclusiOns: Ceritinib in 
the 2nd line treatment of ALK+ NSCLC leads to an increase in total health care costs 
due to improved survival which produces longer treatment duration.
